Company intelligence / Profile preview

Vaxess Technologies

Cambridge, Massachusetts, United Statesvaxess.com ↗
Ownership
Private
Employees
~42
Development stage
Other
01

Overview

Vaxess Technologies has developed the MIMIX™ microneedle patch platform enabling shelf-stable, needle-free transdermal delivery of vaccines and therapeutics. The lead program—a flu vaccine delivered by the MIMIX MAP—has reached Phase I clinical trials. Preclinical data show enhanced immune responses compared to traditional vaccines, including broader protection against drifted strains. The company’s technology eliminates cold chain requirements and enables self-administration at home or in low-resource settings. Additional pipeline programs target infectious diseases, metabolic disorders with GLP‑1 analogs, mRNA-based therapies, and cancer immunotherapy.

Therapeutic areas
Metabolic DisordersOncologyInfectious Diseases
Modalities
Vaccines (including mRNA and virus-like particles)Biologics (e.g., GLP‑1 analogs)ImmunotherapiesMicroneedle/Transdermal delivery systems (MIMIX patch)
Industry
Biotech
02

Drug pipeline

3 assets

VX-103

1

2 more assets in the full pipeline.

03

Partnerships

AstraZeneca ($10M+ partnership on development of microneedle-delivered vaccines)Medigen Vaccine Biologics Co.multiple pharmaceutical companies in joint development partnershipsfunding from BARDA/DARPA/Gates Foundation/NIAID/NIH/NSF

Beyond the preview

Go deeper on Vaxess Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxess Technologies.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call